# Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach

**Authors:** Karolina Drożdż, Katarzyna Nabrdalik, Hanna Kwiendacz, Mirela Hendel, Anna Olejarz, Andrzej Tomasik, Wojciech Bartman, Jakub Nalepa, Janusz Gumprecht, Gregory Y. H. Lip

PMC · DOI: 10.1186/s12933-022-01672-9 · Cardiovascular Diabetology · 2022-11-12

## TL;DR

This study uses machine learning to identify key risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease.

## Contribution

The study introduces a machine learning approach to uncover the most important CVD risk factors in patients with MAFLD.

## Key findings

- Hypercholesterolemia, plaque scores, and diabetes duration were key risk factors for CVD in MAFLD patients.
- Machine learning models achieved high accuracy in identifying high-risk patients with AUC values up to 0.87.
- The best model correctly identified 79.17% of low-risk and 85.11% of high-risk patients.

## Abstract

Nonalcoholic fatty liver disease is associated with an increased cardiovascular disease (CVD) risk, although the exact mechanism(s) are less clear. Moreover, the relationship between newly redefined metabolic-associated fatty liver disease (MAFLD) and CVD risk has been poorly investigated. Data-driven machine learning (ML) techniques may be beneficial in discovering the most important risk factors for CVD in patients with MAFLD.

In this observational study, the patients with MAFLD underwent subclinical atherosclerosis assessment and blood biochemical analysis. Patients were split into two groups based on the presence of CVD (defined as at least one of the following: coronary artery disease; myocardial infarction; coronary bypass grafting; stroke; carotid stenosis; lower extremities artery stenosis).

The ML techniques were utilized to construct a model which could identify individuals with the highest risk of CVD. We exploited the multiple logistic regression classifier operating on the most discriminative patient’s parameters selected by univariate feature ranking or extracted using principal component analysis (PCA). Receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) were calculated for the investigated classifiers, and the optimal cut-point values were extracted from the ROC curves using the Youden index, the closest to (0, 1) criteria and the Index of Union methods.

In 191 patients with MAFLD (mean age: 58, SD: 12 years; 46% female), there were 47 (25%) patients who had the history of CVD. The most important clinical variables included hypercholesterolemia, the plaque scores, and duration of diabetes. The five, ten and fifteen most discriminative parameters extracted using univariate feature ranking and utilized to fit the ML models resulted in AUC of 0.84 (95% confidence interval [CI]: 0.77–0.90, p < 0.0001), 0.86 (95% CI 0.80–0.91, p < 0.0001) and 0.87 (95% CI 0.82–0.92, p < 0.0001), whereas the classifier fitted over 10 principal components extracted using PCA followed by the parallel analysis obtained AUC of 0.86 (95% CI 0.81–0.91, p < 0.0001). The best model operating on 5 most discriminative features correctly identified 114/144 (79.17%) low-risk and 40/47 (85.11%) high-risk patients.

A ML approach demonstrated high performance in identifying MAFLD patients with prevalent CVD based on the easy-to-obtain patient parameters.

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995), nonalcoholic fatty liver disease (MONDO:0013209), coronary artery disease (MONDO:0005010), myocardial infarction (MONDO:0005068), stroke (MONDO:0005098), carotid stenosis (MONDO:0001612), diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** ACE (angiotensin I converting enzyme) [NCBI Gene 1636] {aka ACE1, CD143, DCP, DCP1}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** noncommunicable diseases (MESH:D000073296), LSM (MESH:D017093), CAP (MESH:C538265), heart failure (MESH:D006333), MAFLD (MESH:D005234), peripheral artery disease (MESH:D058729), dysmetabolism (MESH:D024821), HbA1c (MESH:D006445), prediabetes (MESH:D011236), IoU (MESH:D017759), T2DM type 2 diabetes mellitus (MESH:D003924), Insulin Resistance (MESH:D007333), atherosclerosis (MESH:D050197), CKD-EPI (MESH:D051436), coronary artery disease (MESH:D003324), Obesity (MESH:D009765), artery stenosis (MESH:D012078), diabetes (MESH:D003920), liver fibrosis (MESH:D008103), Hypertriglyceridemia (MESH:D015228), shoulder (MESH:D000070599), CVD (MESH:D002318), Hypertension (MESH:D006973), atrial fibrillation (MESH:D001281), death (MESH:D003643), DM (MESH:D009223), Plaque (MESH:D003773), Hypercholesterolemia (MESH:D006937), deep vein thrombosis (MESH:D020246), myocardial infarction (MESH:D009203), NAFLD (MESH:D065626), Diabetes Control and Complications (MESH:D048909), hepatic (MESH:D056486), ACC (MESH:D004476), stroke (MESH:D020521), CDD (MESH:C567275), overweight (MESH:D050177), pneumonia (MESH:D011014), fibrosis (MESH:D005355), carotid artery stenosis (MESH:D016893), metabolic abnormalities (MESH:D008659), heart insufficiency (MESH:D000309), CCA (MESH:D002340), cancer (MESH:D009369), liver disease (MESH:D008107)
- **Chemicals:** fibrate (MESH:D058607), Cholesterol (MESH:D002784), TG (MESH:D013866), creatinine (MESH:D003404), lipid (MESH:D008055), glucose (MESH:D005947), alcohol (MESH:D000438), ACEi (-), alanine (MESH:D000409), Triglycerides (MESH:D014280)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC9655870/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC9655870/full.md

## References

54 references — full list in the complete paper: https://tomesphere.com/paper/PMC9655870/full.md

---
Source: https://tomesphere.com/paper/PMC9655870